A Double-Blind, Randomized, Placebo-Controlled, Two-Period Crossover Trial to Assess the Effects of 4 g/d P-OM3 on LDL-C and Other Aspects of the Fasting Lipid Profile in Subjects With Primary Hypercholesterolemia.
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Omega-3-acid ethyl esters (Primary)
- Indications Hypercholesterolaemia
- Focus Biomarker; Therapeutic Use
- 29 Jan 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 23 Sep 2009 Planned initiation date changed from 1 Jul 2009 to 1 Jan 2010 as reported by ClinicalTrials.gov.
- 23 Sep 2009 Planned end date changed from 1 Mar 2010 to 1 Oct 2010 as reported by ClinicalTrials.gov.